Home » Topics » Regulatory

Regulatory
RSS

FDA approves Imfinzi for unresectable stage III NSCLC

Feb. 19, 2018

Gilead Sciences' Harvoni approved for new indication in Japan

Feb. 19, 2018

FDA approves Erleada for non-metastatic castration-resistant prostate cancer

Feb. 15, 2018

FDA approves Symdeko to treat underlying cause of cystic fibrosis

Feb. 13, 2018

FDA approves Biktarvy to treat HIV-1 infection

Feb. 8, 2018

FDA approves Synergy Pharmaceuticals' Trulance for IBS-C

Jan. 26, 2018

EC extends approval of Adcetris to include cutaneous T-cell lymphoma

Jan. 23, 2018

Nailin approved in Japan for onychomycosis

Jan. 23, 2018

Etanercept biosimilar approved in Japan

Jan. 22, 2018

Elobixibat approved in Japan for chronic constipation

Jan. 19, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...